Dr Lee Soo Chin

Dr Lee Soo Chin obtained her medical degrees from the National University of Singapore and the Royal College of Physicians, United Kingdom, and completed a fellowship in cancer genetics at Johns Hopkins School of Medicine, United States. She is currently a Senior Consultant in Medical Oncology and Assistant Director of Research at the National University Cancer Institute, Singapore, and Senior Principal Investigator at the Cancer Science Institute, Singapore. She was the Chairperson of the Chapter of Medical Oncologists, Academy of Medicine, Singapore from 2009-2011, and sits on several National committees, including the Health Sciences Authority Pharmacogenetics Advisory Committee and the breast and colorectal cancer screening committees at the Ministry of Health. She has been the Chairperson of the National Healthcare Group Domain-Specific Ethics Review Board since 2008. She specializes in breast cancer and directs the Cancer Genetics program at the National University Hospital, Singapore. Her research focus is on breast cancer, pharmacogenetis and cancer genetics, and she is the Principal Investigator of several multi-centre as well as investigator-initiated breast cancer clinical trials. She was awarded the Singapore National Medical Research Council Senior Clinician Scientist Award in 2009, and has more than 70 peer-reviewed publications in major oncology and pharmacogenetics journals, including Cancer, Oncology, Journal of Clinical Oncology, Clinical Pharmacology and Therapeutics, Pharmacogenetics and Genomics, Breast Cancer Research and Treatment and New England Journal of Medicine. She is a member of the Editorial Board of Asia Pacific Journal of Clinical Oncology, and has reviewed for international journals including Gut, British Journal of Cancer, Pharmacogenetics and Genomics, Personalized Medicine, Annals of Oncology, Cancer Chemotherapy and Pharmacology, and Pharmacogenomics.

Education and Fellowships

MBBS (S'pore), MRCP, M Med (Int Med), Familial Cancer Risk Assessment and Management Credential (Institute for Clinical Evaluation, USA)

Specialty Interests

• Breast cancer
• Cancer genetics
• Pharmacogenetics

Awards and Honours

• HMDP Fellowship (FY2000) for cancer genetics fellowship with the John Hopkins University, USA, March 1999 to August 2000
• NUH STAR award for excellent clinical service (individual), 2005
• National Medical Research Clinical Junior Clnician Scientist Investigator Award, 2006
• National Healthcare Group Dr Ang Ah Ling Research Ethics Training Award, 2009
• A*STAR Clinician Scientist Award (Senior Investigator), 2009

Professional Memberships

• Member, American Society of Clinical Oncology
• Fellow and Past Chairperson, Chapter of Medical Oncologists, Academy of Medicine, Singapore Member, Singapore Society of Oncology

Selected Publications (out of 74)

1. Effects of CYP4F2 and GGCX genetic variants on maintenance warfarin dose in a multi-ethnic Asian population. SL Chan, BC Goh, KS Chia, B Chuah, A Wong, R Lim, SC Lee. Thrombosis and Haemostasis 2011; 105(6)
2. Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies. WP Yong, BC Goh, RA Soo, HC Toh, K Ethirajulu, J Wood, V Novotny-Diermayr, SC Lee, WL Yeo, D Chan, D Lim, E Seah, R Lim, J Zhu. In press. Annals of Oncology 2011.
3. Prognostic value of axillary lymph node status after neoadjuvant chemotherapy. Results from a multicenter study. N Saxena, M Hartman, R Aziz, E Rapit, NB Pathy, SE Lim, P Iau, NA Tiab, I Neyroud-Caspar, V Vinh-Hung, CH Yip, SC Lee, HM Verkooijen. Eur J Cancer 2011. In press
4. Serial changes in the expression of breast cancer-related proteins in response to neoadjuvant chemotherapy. BYS Chuah, T Putti, M Salto-Tellez, A Charlton, P Iau, SA Buhari, CI Wong, SH Tan, ALA Wong, CW Chan, BC Goh, SC Lee. Annals of Oncology 2011. In press
5. Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. B Chuah, BC Goh, SC Lee, R Soong, F Lau, M Mulay, M Dinolfo, SE Lim, R Soo, T Furuie, K Saito, C Zerbegel, L Rosen. Cancer Science 2011; 102(2): 478-83
6. Exon sequencing and association analysis of EPHX1 genetic variants with maintenance warfarin dose in a multi-ethnic Asian population. SL Chan, A Thalamuthu, BC Goh, KS Chia, B Chuah, A Wong, SC Lee. Pharmacogenetics and Genomics 2011, 21(1): 35-41
7. Impact of older age on presentation, management and outcome of breast cancer in the multi-ethnic Asian population of Singapore. N Saxena, M Hartman, Z Hussain, NB Pathy, P Iau , SE Lim, JEL Wong, KH Lee, SC Lee, HM Verkooijen. Journal of Geriatric Oncology, 2010. In press.
8. Pharmacokinetics and pharmacodynamis of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients. YW Lim, BC Goh, LZ Wang, SH Tan, B Chuah, SE Lim, P Iau, SA Buhari, CW Chan, N Sukri, MT Cordero, R Soo, SC Lee. Ann Oncol 2010 Apr 29 (epub ahead of print).
9. Phase III randomized trial of sunitnib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. CH Barrios, MC Liu, SC Lee, L Vanlemmens, J-M Ferrero, T Tabei, X Pivot H Iwata, K Aogi, R Lugo-Quintana, Na Harbeck, MJ Brickman, K Zhang, KA Kern, M Martin. Breast Cancer Research and Treatment 2010; 121(1): 121-31.
10. Clinical implications of chemotherapy-induced tumor gene expression in human breast cancers. SH Tan, SC Lee. Expert Opinion on Drug Metabolism and Toxicology 2010; 6(3): 283-306.
11. Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes. D Chan, WL Yeo, MT Cordero, CI Wong, B Chuah, R Soo, SH Tan, SE Lim, BC Goh, SC Lee. Investigational New Drug 2009 Aug 25 (Epub ahead of print).
12. Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer. SC Lee, X Xu, WJ Chng, M Watson, YW Lim, CI Wong, P Iau, N Sukri, SE Lim, HL Yap, SA Buhari, P Tan, JY Guo, B Chuah, HL McLeod, BC Goh. Pharmacogenetics and genomics 2009; 19(11): 833-42.
13. Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. CI Wong, TS Koh, R Soo, S Hartono, CH Thng, E McKeegan, WP Yong, CS Chen, SC Lee, J Wong, R Lim, N Sukri, SE Lim, AB Ong, J Steinberg, N Gupta, R Pradhan, R Humerickhouse, BC Goh. J Clin Oncol 2009; 27(28): 4718-26.
14. Chemotherapy-induced tumor gene expression changes in human breast cancers. SC Lee, X Xu, YW Lim, P Iau, N Sukri, SE Lim, HL Yap, WL Yeo, P Tan, SH Tan, H McLeod, BC Goh. Pharmacogenetics and Genomics 2009; 19: 181-92.
15. Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer. WS Hsieh, R Soo, BK Peh, T Loh, DF Dong, D Soh, LS Wong, S Green, J Chiao, CY Cui, YF Lai, SC Lee, B Mow, R Soong, M Salto-Tellez, BC Goh. Clin Cancer Research 2009; 15(4): 1435-42.
16. Estimation of the warfarin dose with clinical and pharmacogenetic data. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA, Chen YT, Wen MS, Caraco Y, Achache I, Blotnick S, Muszkat M, Shin JG, Kim HS, Suarez-Kurtz G, Perini JA, Silva-Assunção E, Anderson JL, Horne BD, Carlquist JF, Berg RL, Burmester JK, Goh BC, Lee SC, Kamali F, Sconce E, Daly AK, Wu AH, Langaee TY, Feng H, Cavallari L, Momary K, Pirmohamed M, Jorgensen A, Toh CH, Williamson P, McLeod H, Evans JP, Weck KE, Brensinger C, Nakamura Y, Mushiroda T, Veenstra D, Meckley L, Rieder MJ, Rettie AE, Wadelius M, Melhus H, Stein CM, Schwartz U, Kurnik D, Lenzini P, Eby C, Chen LY, Deloukas P, Motsinger-Reif A, Altman RB, Sagreiya H, Srinivasan BS, Eriksson N, Lantz E, Chang T, Ritchie M, Deych E, Lu LS, Shin JG, Srinivasan BS. New England Journal of Medicine 2009; 360(8): 753-64.
17. Pharmacogenetics in Breast Cancer Therapy. SH Tan, SC Lee, BC Goh, J Wong. Clin Cancer Research 2008; 14(24): 8027-41.
18. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity. L Fan, BC Goh, CI Wong, N Sukri, SE Lim, SH Tan, JY Guo, R Lim, HL Yap, YM Khoo, P Iau, HS Lee, SC Lee. Pharmacogenetics and genomics 2008; 18(7): 623-31.
19. Lack of association of single nucleotide polymorphisms in PXR, HNF4α and CAR with docetaxel pharmacokinetics. LS Tham, N Holford, SY Hor, T Tan, LZ Wang, RC Lim, HS Lee, SC Lee, BC Goh. Clin Cancer Research 2007; 13(23): 7126-32.
20. Inter-ethnic variability in warfarin requirement is explained by VKORC1 genotype in an Asian population. SC Lee, SS Ng, J Oldenburg, PY Chong, S Rost, JY Guo, HL Yap, SC Rankin, HB Khor, TC Yeo, KS Ng, R Soong, BC Goh. Clinical Pharmacology & Therapeutics 2006; 79(3): 197-205.
21. Acceptance, motivators and barriers in attending breast cancer genetic counseling in Asian. TM Chin, SH Tan, SE Lim, P Iau, WP Yong, SW Wong, SC Lee. Cancer Detection and Prevention, 2005; 29(5): 412-8.
22. Novel CYP2C9 genetic variants in Asians and their influence on maintenance warfarin dose. F Zhao, C Loke, SC Rankin, JY Guo, HS Lee, TS Wu, T Tan, WL Lu, TC Yeo, Q Zhang, BC Goh, SC Lee. Clinical Pharmacology and Therapeutics 2004; 76(3): 210-9.
23. BRCA1 c2845insA is a recurring mutation with a founder effect in Singapore Malay women with early onset breast / ovarian cancer. JH Sng, Damayanthi, Azar, SC Lee, JEL Wong, P Iau. J Med Genet 2003; 40(10): e117.
24. Explaining inter-individual variability of pharmacokinetics and pharmacodynamics in Asians through genotyping and phenotyping strategies. BC Goh, SC Lee, LZ Wang, L Fan, JY Guo, E Schuetz, R Lim, HL Lim, AB Ong, HS Lee. J Clin Oncol 2002; 20(17): 3683-90.
25. Utilization of BRCA1/2 genetic testing in the clinical setting: report from a single institution. SC Lee, BA Bernhardt, KJ Helzlsouer. Cancer 2002; 94(6): 1876-85.